Schwartz, G. G., Szarek, M. M., Bhatt, D. L., Bittner, V. A., Bregeault, M.-F., Dalby, A. J., … Steg, P. G. (2018). Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. In CIRCULATION (Vol. 138, pp. E772–E773). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.

Schwartz, Gregory G., Michael M. Szarek, Deepak L. Bhatt, Vera A. Bittner, Marie-France Bregeault, Anthony J. Dalby, Rafael Diaz, et al. “Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment.” In CIRCULATION, 138:E772–73. LIPPINCOTT WILLIAMS & WILKINS, 2018.

Schwartz GG, Szarek MM, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, et al. Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2018. p. E772–3.

Schwartz, Gregory G., et al. “Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment.” CIRCULATION, vol. 138, no. 25, LIPPINCOTT WILLIAMS & WILKINS, 2018, pp. E772–73.

Schwartz GG, Szarek MM, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Steg PG. Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2018. p. E772–E773.